Irritable Bowel Syndrome Treatment Market Size Worth Around US$ 3.4 Bn by 2026
16 juil. 2019 14h00 HE
|
Acumen Research and Consulting
Acumen Research and Consulting, Recently Published Report titled “Irritable Bowel Syndrome Treatment Market Size, Share, Trends, Growth and Forecast 2019-2026”. LOS ANGELES, July 16, 2019 (GLOBE...
Metacrine Reports Positive Interim Results with Sustained FXR Agonist in NASH Patients
29 mai 2019 07h30 HE
|
Metacrine, Inc.
SAN DIEGO, May 29, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
Metacrine to Present Relevance of FXR and Specific FXR Drug Profiles for Possible Treatment of Inflammatory Bowel Disease at Digestive Disease Week 2019
13 mai 2019 07h30 HE
|
Metacrine, Inc.
SAN DIEGO, May 13, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
Biomerica Announces Notice of Allowance for New U.S. Patent Application Covering Diagnostic Guided Therapy for Irritable Bowel Syndrome (IBS)
08 avr. 2019 08h19 HE
|
Biomerica, Inc.
IRVINE, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for...
Why IBS Affects Women Differently: A Capital Digestive Care GI Explains
26 févr. 2019 08h24 HE
|
Capital Digestive Care
Silver Spring, MD, Feb. 26, 2019 (GLOBE NEWSWIRE) -- By Leigh Lurie, MD IBS (irritable bowel syndrome) affects about 10% of the global population, making it the most common GI disorder in the...
RedHill Biopharma Announces Positive End-of-Phase II Meeting with FDA on BEKINDA® for IBS-D
12 sept. 2018 07h00 HE
|
RedHill Biopharma Ltd.
The positive Type B meeting with the FDA followed a successful Phase II study of BEKINDA® for diarrhea-predominant irritable bowel syndrome (IBS-D), one of the most common gastrointestinal disorders ...
Metacrine Appoints Hubert Chen, M.D. as Chief Medical Officer and Andrew Guggenhime to the Board of Directors
06 sept. 2018 07h30 HE
|
Metacrine, Inc.
SAN DIEGO, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., a biotechnology company developing therapies to benefit patients with liver and gastrointestinal diseases (GI), today announced the...
Biomerica Announces Fiscal Year End 2018 Financial Results
30 août 2018 08h19 HE
|
Biomerica, Inc.
IRVINE, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported net sales for the fiscal year 2018 were $5,564,185...
AXIM® Biotechnologies to Present at BIT’s 16th Annual Congress of International Drug Discovery Science and Technology
15 août 2018 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Aug. 15, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, today announced that the Company will be...
Biomerica Receives Notice of Allowance for Irritable Bowel Syndrome (IBS) Test Panel and Methods in Korea
02 août 2018 08h19 HE
|
Biomerica, Inc.
IRVINE, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) announced today that the Korean Intellectual Property Office (KIPO) has issued a Notice of Allowance for a patent...